Cantor Fitzgerald raises Ameresco stock price target on Neogenyx deal By Investing.com

Cantor Fitzgerald raised its price target on Ameresco to $45 from $41 while keeping an Overweight rating, implying about 45% upside from the $31.02 share price. The firm lifted its FY2026 revenue estimate to $2.15 billion and FY2026 EPS to $1.15, though it cut FY2027 EPS to $1.83 from $2.08 to reflect the new Neogenyx joint venture structure. Ameresco also received $100 million in direct proceeds from the biofuels JV closing, but the article notes recent quarter results were mixed, with revenue beating estimates while EPS missed.

Analysis

AMRC’s setup is less about a clean fundamental rerating and more about the market being forced to re-underwrite the mix of earnings quality. The joint venture monetization de-risks the balance sheet and crystallizes value in a way that should support the stock on pullbacks, but it also makes near-term per-share metrics look artificially choppy as minority interest and accounting mechanics work through the model. That creates a window where the equity can outperform on narrative while still looking expensive on headline P/E, which tends to keep fundamental longs from pressing too aggressively.

The second-order winner is HASI: even if the market frames this as an AMRC-positive strategic separation, HASI is effectively buying into a de-risked, capital-intensive platform with cleaner project-level economics and optionality on future financings. The more important spillover is competitive — asset-heavy renewable infrastructure players without similar capital recycling options may face a tighter cost of capital as investors compare them against a sponsor that can monetize assets, retain control, and redeploy proceeds. That can compress relative valuation multiples across the broader green infrastructure group over the next 1-2 quarters.

The contrarian angle is that the move may be underestimating execution risk in the post-spin reporting cadence. When a business transitions from simple consolidated growth to a JV-heavy structure, any miss on EBITDA can be misread as operating deterioration even if it is purely allocation noise; that usually produces one or two sharp post-earnings dislocations before the Street normalizes. If the core platform can keep revenue growth intact while the market digests the accounting reset, the stock can grind higher over 3-6 months; if not, the high multiple leaves little cushion and a 15-20% drawdown is plausible on any guidance hiccup.

Key Decisions for Investors

• Long AMRC on weakness for a 3-6 month horizon; use pullbacks toward the low-30s as entry, targeting a re-rating toward the mid-40s as the JV structure is absorbed. Risk: any operational miss that gets mistaken for core deterioration could compress the multiple back toward low-20s forward earnings.
• Pair trade: long AMRC / short a basket of lower-quality renewable infrastructure peers that lack similar capital recycling optionality. The thesis is that AMRC can monetize assets without losing growth, while weaker peers face funding pressure as rates stay elevated.
• Tactically long HASI into the next financing/JV disclosure cycle for 1-3 months if the market continues to reward de-risked renewable capital providers. Risk/reward improves if the market views the Neogenyx structure as validation of HASI’s underwriting franchise rather than a one-off deal.
• Use AMRC call spreads rather than outright stock for a 2-4 month catalyst window; the implied upside is meaningful, but the valuation already embeds a lot of optimism, so defined-risk exposure is preferable.
• Avoid chasing the broader clean-energy complex until the market distinguishes between accounting-driven EPS volatility and true operating misses; this name can set a misleading read-through for the sector over the next quarter.